Identifying Stage B colorectal cancer patients at high risk of tumor recurrence and death

1997 ◽  
Vol 40 (3) ◽  
pp. 326-331 ◽  
Author(s):  
Hugh E. Mulcahy ◽  
Mary Toner ◽  
Stephen E. Patchett ◽  
Leslie Daly ◽  
Diarmuid P. OʼDonoghue
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Tumor Recurrence ◽  
Colorectal Cancer Patients

scholarly journals Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 393
Author(s):  
Alexander Hendricks ◽  
Anu Amallraja ◽  
Tobias Meißner ◽  
Peter Forster ◽  
Philip Rosenstiel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
High Risk ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Standard Of Care ◽  
High Risk Patients ◽  
Risk Patients ◽  
Individualized Treatments ◽  
Colorectal Cancer Patients

Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. Results: Kaplan–Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (p < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. Conclusions: High-risk patients appear to survive significantly longer (p < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines.

18 F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients

2014 ◽  
Vol 83 (12) ◽  
pp. 2224-2230 ◽  
Author(s):  
Germán Andrés Jiménez Londoño ◽  
Ana María García Vicente ◽  
Victoria Sánchez Pérez ◽  
Fátima Jiménez Aragón ◽  
Alberto León Martin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Colorectal Cancer Patients

Colorectal cancer susceptibility variants and clinical outcome in adjuvant and metastatic colorectal cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4051-4051
Author(s):  
H. Lenz ◽  
G. Lurje ◽  
C. A. Haiman ◽  
D. Yang ◽  
A. Pohl ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
Clinical Outcome ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Tumor Recurrence ◽  
Cancer Susceptibility ◽  
Locally Advanced ◽  
Germline Variants ◽  
Colorectal Cancer Patients

4051 Background: Recent genome-wide association studies had identified colorectal cancer susceptibility loci on chromosomes 8q24 (rs6983267), 15q13(rs4779584), 18q21(rs4939827, rs12953717 and rs4464148), 10p14(rs10795668) and 8q23.3(rs16892766). Although the function role of these germline variants are unclear, given the importance of these variants and colorectal cancer risk, we have carried out the first pilot study to explore the association of these variants and clinical outcome. We used pooled data from two CRC-cohorts (locally advanced and metastatic CRC), and investigated the hypothesis that these germline variants may be associated with clinical outcome in adjuvant and metastatic colorectal cancer patients. Methods: Whole blood was collected from 515 patients with locally advanced (n=197) and metastatic CRC (n=318). After extraction of genomic-DNA, germline variants were genotyped as previously described (Haiman et al, Nat Genet, 2007). The genotype success rate was 98%. Blinded repeat samples (5%) were included for quality control purposes; genotype concordance was ≥ 99%. Results: Our results suggest that rs10795668 at 10p14 and rs719725 are significantly associated with time to tumor recurrence in adjuvant colorectal cancer patients, patients with rs10795668 AA genotype had significantly increased risk of time to tumor recurrence compared with those harboring G allele (TG+GG) patients(p=0.05, log-rank test). In metastatic cancer patients, we found rs4939827 at 18q21.1 were significantly associated with overall survival in female patients and rs10795668 at 10p14 were significantly associated with OS in male patients, respectively (p<0.05). Conclusions: Our preliminary results suggest cancer risk alleles may also associated with clinical outcome in adjuvant and metastatic colorectal cancer. Moreover, this correlation is sex-specific in metastatic colorectal cancer. Further comprehensive trials warranted to confirm our pilot findings. [Table: see text]

A Smad4-modulated Wnt target gene expression profile identifies high-risk colorectal cancer patients

2012 ◽  
Vol 215 (3) ◽  
pp. S30-S31
Author(s):  
J. Joshua Smith ◽  
Tanner J. Freeman ◽  
Xi Chen ◽  
Natasha G. Deane ◽  
Mary K. Washington ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Target Gene ◽  
Target Gene Expression ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document